The Boztug Lab at LBI-RUD, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, seeks to fill the open full-time position of a
POSTDOCTORAL FELLOW (reference code: #PD/KB16)
The focus of the group is on the identification of rare monogenic disorders of the immune system and hematopoiesis to explain pathophysiological manifestations in humans (Boztug K at al Nature Genet 2014, Willmann K et al Nature Commun 2014, Dobbs K et al New Engl J Med 2015). In the context of this work, the Boztug group applies a combination of state-of-the-art genetic and genomic technologies including next generation sequencing, and a wide range of cellular and molecular techniques to elucidate novel pathways important for immune system homeostasis.
The group works in a fully equipped molecular biology laboratory in a shared environment with cell culture, multi-color flow cytometry as well as all equipment needed for state-of-the-art genomic investigations such as SNP arrays and deep sequencing, which are immediately accessible in-house.
We are looking for a highly motivated and well-organized Postdoctoral Fellow to join one of the following projects:
Project 1: Deciphering the molecular basis of autoimmunity and autoinflammation
Due to their heterogeneity and prevalence, autoimmune diseases pose a major health problem to modern societies. We have recently identified several novel disease-causing genes in patients with model autoimmune disorders such as early-onset IBD (Glocker*, Kotlarz*, Boztug* et al NEJM 2009; Salzer et al JACI 2014) and early-onset SLE-like diseases (Salzer*, Santos-Valente* et al Blood 2013). This exciting project aims at identifying novel genes within a patient cohort of genetically undiagnosed autoimmune disorders by a variety of biochemical, immunological and imaging technologies to obtain molecular gene-to-phenotype relationships.
Project 2: Identifying and understanding novel types of combined immunodeficiency
Combined immunodeficiencies (CIDs) comprise a large proportion of primary immunodeficiencies. Recently our group has significantly contributed to the field by discovery and detailed molecular description of novel types of CID affecting NF-kB signaling and cellular motility, respectively (Willmann*, Klaver* et al Nature Commun 2014; Dobbs*, Dominguez-Conde* et al New Engl J Med 2015), however to date many CID etiologies still remain undefined, precluding precise treatment recommendations. The proposed project aims to identify novel genes using NGS technology to discover additional cellular pathways underlying CIDs on an ever-growing cohort of patient samples present in the lab.
Project 3: Dissecting molecular pathomechanisms of PIDs using small molecule screens
The translational value of research on PIDs lies in the ability to develop mechanism-based tailored treatment options often hindered by lack of knowledge about molecular pathways underlying the disease. The candidate will develop hypothesis-driven early drug discovery research for few carefully selected PID targets by performing genetic and small molecule screens using the state-of-the-art haploid cell and chemical screening platforms combined with a comprehensive drug library, all available in-house (in collaboration with CeMM PI Stefan Kubicek; e.g. Winter et al Nature Chem Biol 2014; Jae et al Science 2014).